Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01623479 · ClinicalTrials.gov registry record
An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 585
- Enrollment target
NCT01623479: Completed study, sponsored by Allergan.
NCT01623479 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 585 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01623479 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 585 participants
- Enrollment target
Study Summary
This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
Primary Outcome
Overall subject satisfaction with Latisse® was assessed on a 5-point scale (Very Satisfied, Satisfied, Neutral, Unsatisfied, and Very Unsatisfied). The percentage of subjects satisfied and very satisfied is reported.
Interventions
- DRUG bimatoprost 0.03%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 585 participants |
| Start Date | 2010-11-19 |
| Est. Completion | 2011-09-01 |
What the finished NCT01623479 record still lists
NCT01623479 is an observational study that tracks outcomes without assigning an intervention. The registered 585 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which bimatoprost 0.03% is the first listed.
NCT01623479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01623479 about?
NCT01623479 is a clinical study titled "An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes". This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
What is the current status of trial NCT01623479?
This trial is currently completed. The enrollment target is 585 participants. The study started on 2010-11-19. Estimated completion is 2011-09-01.
What interventions are being tested in trial NCT01623479?
The interventions under investigation include: bimatoprost 0.03% (DRUG).
Who is sponsoring clinical trial NCT01623479?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02803957 · 585 participants · NA
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
- NCT06680869 · 585 participants · Phase 3
Early Amiodarone in Shockable Cardiac Arrest
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI